non-small-cell lung cancer
Conditions
Interventions
None listed
Sponsors
Clinical Research Support Center Kyushu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with EGFR gene mutation (exon 19 deletion, L858R, G719X, L861M, T790M, etc) -positive non-small-cell lung cancer determined with a histological diagnosis or cytodiagnosis. 2)Patients with treatment plan of EGFR-TKI alone or combination therapy including EGFR-TKI. In addition, plasma samples of patients before treatment are stored at -80 degrees Celsius even if after the start of treatment. 3)Patients with more than 20 years. 4)Patients providing written informed consent.
Exclusion criteria
Exclusion criteria: 1) Patient with positive HBs antigen or HVC antibody. 2) Patient with definite positive HIV antibody (need not for examination). 3) Any other patients who are regarded as unsuitable for this study by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection of EGFR gene mutation from cfDNA collected before and after treatment with EGFR-TKI in patients with EGFR gene mutation- positive non-small-cell lung cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Detection of a biomarker about EGFR-TKI tolerance. Coincidence ratio of detection of EGFR gene mutation between tissue samples and cfDNA. Association between the clinical background including a presence or absence of T790M gene mutation and the prognosis. | — |
Countries
Japan
Contacts
Public ContactNoriko Hidaka
Graduate School of Medical Sciences, Kyushu University Research Institute for Disease of the Chest
Outcome results
None listed